Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 4/20 | 0.42 |
| ▸ | PGK1 | P00558 | 1/20 | 0.42 |
| ▸ | PGK2 | P07205 | 1/20 | 0.42 |
| ▸ | PGD | P52209 | 4/20 | 0.40 |
| ▸ | MPI | P34949 | 1/20 | 0.40 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.37 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.37 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.37 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.37 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21132793 | 0.86 | PLA2G2A (0.50) | PLA2G4APGD | |
| SCHEMBL17035824 | 0.72 | PAX8 (0.43) | — | |
| SCHEMBL1862619 | 0.72 | PGD (0.53) | PGK1PGK2PGDMPILPAR5 | |
| SCHEMBL25260286 | 0.72 | PGD (0.53) | PGK1PGK2PGDMPILPAR5 | |
| SCHEMBL29355121 | 0.72 | PGD (0.53) | PGK1PGK2PGDMPILPAR5 | |
| SCHEMBL9025911 | 0.71 | TRPV1 (0.31) | — | |
| SCHEMBL12242916 | 0.71 | TACR1 (0.33) | — | |
| SCHEMBL15003218 | 0.71 | TACR1 (0.33) | — | |
| SCHEMBL15003158 | 0.71 | TRPV1 (0.31) | — | |
| SCHEMBL12000903 | 0.71 | PLA2G4A (0.38) | PLA2G4APGDLPAR1LPAR2LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11000587-B2 | Use as immune enhancer or pharmaceutical composition for treatment of dementia, comprising phytosphingosine-1-phosphate or derivative thereof | AXCESO BIOPHARMA CO., LTD. (KR) | 2021-05-11 | — | — | US | disclosed |
| US-20200046829-A1 | USE AS IMMUNE ENHANCER OR PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DEMENTIA, COMPRISING PHYTOSPHINGOSINE-1-PHOSPHATE OR DERIVATIVE THEREOF | AXCESO BIOPHARMA CO., LTD. (KR) | 2020-02-13 | — | — | US | disclosed |
| US-20190292521-A1 | COMPOSITION FOR PROMOTING GROWTH OF STEM CELLS COMPRISING PHYTOSPHINGOSINE-1-PHOSPHATE OR DERIVATIVES THEREOF, AND COMPOSITION FOR CULTURING MEDIA OF STEM CELLS COMPRISING SAME | AXCESO BIOPHARMA CO., LTD. (KR) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11000587-B2 | Use as immune enhancer or pharmaceutical composition for treatment of dementia, comprising phytosphingosine-1-phosphate or derivative thereof | NANS, PSEN1, ENPP1 | PLA2G4A 131/4885PGK1 700/4885PGK2 1779/4885 |
| US-20200046829-A1 | USE AS IMMUNE ENHANCER OR PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DEMENTIA, COMPRISING PHYTOSPHINGOSINE-1-PHOSPHATE OR DERIVATIVE THEREOF | NANS, PSEN1, ENPP1 | PLA2G4A 131/4885PGK1 700/4885PGK2 1779/4885 |
| US-20190292521-A1 | COMPOSITION FOR PROMOTING GROWTH OF STEM CELLS COMPRISING PHYTOSPHINGOSINE-1-PHOSPHATE OR DERIVATIVES THEREOF, AND COMPOSITION FOR CULTURING MEDIA OF STEM CELLS COMPRISING SAME | NANS, PAPSS1, STIP1 | PLA2G4A 201/4885PGK1 429/4885PGK2 892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.